BioSpace News Archive

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format.

ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”) today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a virtual fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Tuesday, April 4th at 10:45 am ET, as well as 1x1 meetings with investors.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full-year 2022 and summarized recent business highlights.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the twelve months ended December 31, 2022.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will release its fourth quarter 2022 financial results along with its Form 10-K on Friday, March 31, 2023.

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it has commenced an underwritten public offering of its ordinary shares, no par value.

NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for the fourth quarter and full year 2022.